Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.96 |
| ▸ | TSHR | P16473 | 1/20 | 0.96 |
| ▸ | CA1 | P00915 | 5/20 | 0.59 |
| ▸ | CA2 | P00918 | 5/20 | 0.59 |
| ▸ | CA9 | Q16790 | 5/20 | 0.59 |
| ▸ | CA12 | O43570 | 4/20 | 0.59 |
| ▸ | CA7 | P43166 | 4/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | CFTR | P13569 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | HPGD | P15428 | 4/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.57 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.57 |
| ▸ | CA5A | P35218 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl Salicylate SCHEMBL28560813 | 0.98 | LMNA (0.92) | LMNATSHRCA1CA2CA9 | |
| Methyl Salicylate SCHEMBL29370254 | 0.98 | LMNA (1.00) | LMNATSHRCA1CA2CA9 | |
| Methyl Salicylate SCHEMBL1872042 | 0.98 | LMNA (1.00) | LMNATSHRCA1CA2CA9 | |
| Methyl Salicylate SCHEMBL5312 | 0.98 | LMNA (1.00) | LMNATSHRCA1CA2CA9 | |
| Methyl Salicylate SCHEMBL23045204 | 0.96 | LMNA (0.96) | LMNATSHRCA1CA2CA9 | |
| Methyl Salicylate SCHEMBL30721422 | 0.96 | LMNA (0.96) | LMNATSHRCA1CA2CA9 | |
| Methyl Salicylate SCHEMBL7961805 | 0.96 | LMNA (0.96) | LMNATSHRCA1CA2CA9 | |
| Methyl Salicylate SCHEMBL5795853 | 0.96 | LMNA (0.96) | LMNATSHRCA1CA2CA9 | |
| Methyl Salicylate SCHEMBL29020443 | 0.96 | LMNA (0.96) | LMNATSHRCA1CA2CA9 | |
| Methyl Salicylate SCHEMBL7961798 | 0.96 | LMNA (0.96) | LMNATSHRCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1394 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250041216-A1 | Methotrexate Composition | ROSEMONT PHARMACEUTICALS LTD (GB) | 2025-02-06 | — | — | US | claimed |
| US-11969503-B2 | Methotrexate composition | ROSEMONT PHARMACEUTICALS LTD (GB) | 2024-04-30 | — | — | US | claimed |
| CN-117065037-A | Pharmaceutical compositions comprising S1P modulators | 诺华股份有限公司 | 2023-11-17 | — | — | CN | claimed |
| US-20230233464-A1 | Methotrexate Composition | ROSEMONT PHARMACEUTICALS LTD (GB) | 2023-07-27 | — | — | US | claimed |
| CN-114948868-B | Crystal form of lamotrigine hydrate, preparation method thereof and composition containing crystal form | 上海奥科达医药科技股份有限公司 | 2023-04-14 | — | — | CN | claimed |
| CN-113679958-B | Equivalent tissue compensator and preparation method thereof | 无锡恒成医疗科技股份有限公司 | 2023-03-24 | — | — | CN | claimed |
| CN-115778897-A | Stable methotrexate pharmaceutical preparation and preparation method thereof | 深圳市贝美药业有限公司 | 2023-03-14 | — | — | CN | claimed |
| CN-115721634-A | Tomoxetine hydrochloride composition, preparation method thereof and application thereof in oral solution | 海南卓科制药有限公司 | 2023-03-03 | — | — | CN | claimed |
| CN-115721706-A | Composition for treating eczema dermatitis and preparation method and application thereof | 湖南天根乐微君科技有限公司 | 2023-03-03 | — | — | CN | claimed |
| CN-115677873-A | Tremella polysaccharide and application thereof in preparation of anti-aging composition | 石家庄瑞大圣康生物科技有限公司 | 2023-02-03 | — | — | CN | claimed |
| US-20030130267-A1 | Pharmaceutical composition | SPECIAL PRODUCTS LIMITED | 2003-07-10 | — | — | US | claimed |
| EP-1323422-A1 | Pharmaceutical composition comprising midazolam for buccal administration | Special Products Limited (GB) | 2003-07-02 | — | — | EP | claimed |
| CN-1089583-C | Mycophenolic acid 2- (4-morpholino) ethyl ester high-dose oral suspension | SYNTEX INC (US) | 2002-08-28 | — | — | CN | claimed |
| CN-1069519-C | Bulleyaconitine A soft capsule and its production method | KUNMING PHARMACEUTICAL CO LTD (CN) | 2001-08-15 | — | — | CN | claimed |
| CN-1069520-C | Breviscapine soft capsule and its production method | KUNMING PHARMACEUTICAL CO LTD (CN) | 2001-08-15 | — | — | CN | claimed |
| CN-1286623-A | Tooth desensitizing compositions | ITALMED S N C DI GALLI G E PAC (IT) | 2001-03-07 | — | — | CN | claimed |
| CN-1256706-A | Non-drying adhesive composition for treating surfaces | HENKEL ECOLAB GMBH & CO OHG (DE) | 2000-06-14 | — | — | CN | claimed |
| CN-1228959-A | Breviscapine soft capsule and its production method | KUNMING PHARMACEUTICAL CO LTD (CN) | 1999-09-22 | — | — | CN | claimed |
| CN-1225581-A | Use of alpha blockers, in particular of thymol amine and/or its derivatives for the treatment of penile erectile dysfunction by the transmucosal glans route | BIOTEC CENTRE SA (FR) | 1999-08-11 | — | — | CN | claimed |
| CN-1132479-A | Mycophenolate mofetil high dose oral suspensions | SYNTEX A INC (US) | 1996-10-02 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130267-A1 | Pharmaceutical composition | CYP3A5, CYP3A7, CYP3A43 | LMNA 1057/4885TSHR 3224/4885CA1 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.